{
  "meta": {
    "title": "Recent_Updates_Mini_Test_-_New_Pattern_20_Questions",
    "url": "https://brainandscalpel.vercel.app/recent-updates-mini-test-new-pattern-20-questions-76b64d2f.html",
    "scrapedAt": "2025-11-30T12:45:43.743Z"
  },
  "questions": [
    {
      "text": "A 37-year-old woman who is a direct contact of a known case of influenza is also found to be positive. She has just had a mild cough and a runny nose over the last 10-12 hours but was completely asymptomatic before that. Her medical history is unremarkable but she is currently on calcium and iron supplements prescribed to her by her GP. She has just been in close proximity with her 14-year-old daughter over the last 2 days. You decide to start her on Baloxavir marboxil (Xofluza). Which of the following statements are true?<div class='question-desc-html'><ol>\n<li>Baloxavir marboxil would not be indicated in this patient if symptoms had been present for more than 48 hours.</li>\n<li>Baloxavir marboxil should be administered orally</li>\n<li>Baloxavir marboxil is an influenza virus polymerase acidic endonuclease inhibitor&nbsp;</li>\n<li>Baloxavir marboxil can be taken simultaneously with iron or calcium supplements</li>\n<li>Baloxavir marboxil can also be used for post-exposure prophylaxis in the patient's daughter</li>\n</ol></div>",
      "choices": [
        {
          "id": 1,
          "text": "1, 2, 3, and 4"
        },
        {
          "id": 2,
          "text": "1, 2, 3, and 5"
        },
        {
          "id": 3,
          "text": "3, 4, and 5"
        },
        {
          "id": 4,
          "text": "1, 4, and 5"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The endonuclease inhibitor indicated for both&nbsp;post-exposure prevention and treatment of acute uncomplicated influenza is <strong>Baloxavir marboxil (Xofluza)&nbsp;</strong>which is available in tablet form to be taken<strong> orally, </strong>and now also as granules for mixing in water <strong>(not nasal spray).</strong></p>\n<p>It was approved by the FDA in 2018. It is used to treat acute&nbsp;<strong>uncomplicated influenza</strong> in patients 12 years of age and older who have been <strong>symptomatic</strong> for <strong>less than 48 hours. </strong>It is a <strong>selective inhibitor of influenza cap-dependent endonuclease</strong> which blocks proliferation by <strong>inhibiting mRNA synthesis.</strong></p>\n<p>Baloxavir inhibits the endonuclease activity of the polymerase acidic protein. Polymerase acidic protein is an influenza virus-specific enzyme in the viral RNA polymerase complex required for viral gene transcription. Inhibiting this results in inhibition of influenza virus replication.</p>\n<p>In November 2020&nbsp;the U.S. FDA <strong>expanded the approved indication</strong> for&nbsp;baloxavir marboxil (Xofluza ) to <strong>include</strong> <strong>post-exposure prevention of influenza</strong> for patients 12 years of age and older after contact with an individual who has the flu.</p>\n<p>The most common side effects of baloxavir marboxil include diarrhea, bronchitis, nausea, sinusitis, and headache.&nbsp;Baloxavir marboxil should <strong>not</strong> be co-administered with dairy products, <strong>calcium-containing</strong>&nbsp;beverages,&nbsp;laxatives, antacids, or oral supplements containing <strong>calcium, iron,</strong> magnesium, selenium, aluminum, or zinc.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD6548",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following refers to X-linked osteopetrosis occurring due to IKBKG mutation?",
      "choices": [
        {
          "id": 1,
          "text": "Albers-Schonberg disease"
        },
        {
          "id": 2,
          "text": "Anhidrotic ectodermal dysplasia"
        },
        {
          "id": 3,
          "text": "Vrolik’s syndrome"
        },
        {
          "id": 4,
          "text": "Brittle bone disease"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>X-linked osteopetrosis</strong> which occurs due to <strong>IKBKG mutation</strong> is also known as <strong>anhidrotic ectodermal dysplasia. </strong></p>\n<p>Osteopetrosis is usually autosomal dominant or autosomal recessive. Rarely, it can have an <strong>X-linked</strong> pattern of inheritance, which occurs due to the <strong>IKBKG mutation</strong> encoding NEMO. It is involved in <strong>NF-kB activation.</strong> </p>\n<p>IKBKG mutations result in a multisystem disorder due to the involvement of NF-kB. It is called X-linked anhidrotic ectodermal dysplasia with immunodeficiency. It includes osteopetrosis.</p>\n<p>Option A:<strong> Albers Schonberg disease</strong> is a mild autosomal dominant form of <strong>osteopetrosis</strong> that is caused by a mutation of CLCN7.</p>\n<p>Options C and D: Vrolik syndrome and brittle bone disease is another name for osteogenesis imperfecta.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD5880",
      "difficulty": "hard"
    },
    {
      "text": "In 2020, the U.S. Food and Drug Administration has approved Inmazeb , a mixture of three monoclonal antibodies, as the first FDA-approved treatment for which of the following deadly diseases?",
      "choices": [
        {
          "id": 1,
          "text": "Corona virus"
        },
        {
          "id": 2,
          "text": "Ebola virus"
        },
        {
          "id": 3,
          "text": "Lyssa virus"
        },
        {
          "id": 4,
          "text": "Nipah virus"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The U.S. Food and Drug Administration approved <strong>Inmazeb (atoltivimab, maftivimab, and odesivimab)</strong>, a mixture of three <strong>monoclonal antibodies</strong>, as the first FDA-approved treatment for <strong>Zaire ebolavirus </strong>(<strong>Ebola virus</strong>) infection in adult and pediatric patients.</p>\n<p>It is indicated for the treatment of infection caused by Zaire ebolavirus in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection.</p>\n<p>Inmazeb targets the <strong>glycoprotein</strong> that is on the surface of the Ebola virus. Glycoprotein attaches to the cell receptor and fuses the viral and host cell membranes allowing the virus to enter the cell. The three antibodies that makeup Inmazeb can bind to this glycoprotein simultaneously and <strong>block attachment and entry of the virus</strong></p>\n<p>Note: Patients who receive Inmazeb should avoid the concurrent administration of a live vaccine due to the treatment’s potential to inhibit replication of a live vaccine virus indicated for the prevention of Ebola virus infection and possibly reduce the vaccine’s efficacy.</p>\n<p><strong><span data-preserver-spaces=\"true\">Ebola virus </span></strong><span data-preserver-spaces=\"true\">is the cause of an emerging disease called Ebola virus disease and is widespread in Africa. It belongs to the </span><strong><span data-preserver-spaces=\"true\">Filoviridae</span></strong><span data-preserver-spaces=\"true\"> family.</span></p>\n<p><strong><span data-preserver-spaces=\"true\">Fruit bats</span></strong><span data-preserver-spaces=\"true\"> act as </span><strong><span data-preserver-spaces=\"true\">reservoir</span></strong><span data-preserver-spaces=\"true\"> hosts of the virus and it is transmitted to humans only accidentally. </span><strong><span data-preserver-spaces=\"true\">Human-to-human transmission</span></strong><span data-preserver-spaces=\"true\"> is through direct contact with blood or body fluids of an infected symptomatic person. </span></p>\n<p><span data-preserver-spaces=\"true\">The incubation period of the disease is </span><strong><span data-preserver-spaces=\"true\">2 to 21</span></strong><span data-preserver-spaces=\"true\"> days. Symptoms include </span><strong><span data-preserver-spaces=\"true\">fever, intense weakness, vomiting, diarrhea, rashes,</span></strong><span data-preserver-spaces=\"true\"> and, in extreme cases, internal and external </span><strong><span data-preserver-spaces=\"true\">bleeding</span></strong><span data-preserver-spaces=\"true\">. The current treatment is mainly supportive. Patients are susceptible to reinfection even after a complete cure.</span></p>\n<p> </p>\n<p><span data-preserver-spaces=\"true\">The electron micrograph image shows <strong>the Ebola virus</strong>.</span></p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/30a4a8bdef7a4c7bb1df5e10b02017a8x720x331.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD5726",
      "difficulty": "medium"
    },
    {
      "text": "Your friend, who is a diabetic, overweight female, seeks your medical opinion on a new method of contraception, called TWIRLA, which her gynecologist had prescribed to her. You would be correct to mention all of the following except:",
      "choices": [
        {
          "id": 1,
          "text": "TWIRLA is contraindicated in women with a BMI ≥ 30 kg/m2"
        },
        {
          "id": 2,
          "text": "TWIRLA delivers drugs transdermally and is applied to the skin as a patch"
        },
        {
          "id": 3,
          "text": "She would need glucose monitoring if she uses TWIRLA"
        },
        {
          "id": 4,
          "text": "It can be applied over the abdomen, buttock, upper torso or even the breasts"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>TWIRLA</strong>, a transdermal contraceptive patch can be applied over the abdomen, buttock, upper torso <strong>but not the breasts.</strong></p>\n<p>The US Food and Drug Administration (FDA) has approved the levonorgestrel and Ethinyl estradiol transdermal system&nbsp;(<strong><em>Twirla</em></strong>) for contraception in women whose body mass index (BMI) is &lt;30 kg/m<sup>2</sup>&nbsp;and for whom a combined hormonal&nbsp;contraceptive&nbsp;is appropriate.</p>\n<p>Applied weekly to the abdomen, buttock, or upper torso (excluding the breasts), Twirla delivers a&nbsp;30-&micro;g daily dose of ethinyl estradiol and a 120-&micro;g daily dose of levonorgestrel.</p>\n<p>Enzyme inducers (e.g., CYP3A4) may decrease the effectiveness of TWIRLA or increase breakthrough bleeding. Women should be advised to use a backup or alternative method of contraception when enzyme inducers are used with TWIRLA.&nbsp;Adverse Carbohydrate and Lipid Metabolic Effect of Twirla necessitates&nbsp;monitoring of glucose in prediabetic and diabetic women using TWIRLA. An alternate<br />contraceptive method should be considered for women with uncontrolled dyslipidemia.</p>\n<p><strong>Contraindications</strong>:</p>\n<ul>\n<li>High risk of arterial or venous thromboembolism diseases&nbsp;</li>\n<li>Breast cancer or other estrogen- or progestin-sensitive cancer&nbsp;</li>\n<li>BMI &ge; 30 kg/m2&nbsp;</li>\n<li>Liver tumors, acute viral hepatitis or decompensated cirrhosis&nbsp;</li>\n<li>Undiagnosed abnormal uterine bleeding</li>\n<li>Pregnancy&nbsp;</li>\n<li>Hypersensitivity reactions to components of TWIRLA</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD4799",
      "difficulty": "hard"
    },
    {
      "text": "A 30-year-old primigravida, in her 21st week of pregnancy, seeks your advice regarding an analgesic for abdominal pain. Which of the following drugs would you not advise as it may cause serious kidney problems in the unborn baby?",
      "choices": [
        {
          "id": 1,
          "text": "Tramadol"
        },
        {
          "id": 2,
          "text": "Paracetamol"
        },
        {
          "id": 3,
          "text": "Ibuprofen"
        },
        {
          "id": 4,
          "text": "Morphine"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The U.S. Food and Drug Administration (FDA) has issued a warning regarding the use of <strong>nonsteroidal anti-inflammatory drugs (NSAIDs) </strong>like<strong> ibuprofen</strong> around or after <strong>20 weeks </strong>of gestation as it may cause rare but serious problems in the <strong>kidneys</strong> of the fetus.</p>\n<p>This can lead to a <strong>decrease in amniotic fluid</strong> levels surrounding the fetus. From 20 weeks onwards, the fetal kidneys produce most of the amniotic fluid.</p>\n<p>NSAIDs, commonly used for anti-inflammatory and analgesic benefits include aspirin, ibuprofen, naproxen, diclofenac, and celecoxib. These recommendations <strong>do not apply</strong> to the use of <strong>low-dose aspirin</strong> during pregnancy and should be taken under the direction of a health care professional.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD5723",
      "difficulty": "medium"
    },
    {
      "text": "A District Leprosy Officer is preparing the annual report as per NLEP 2020. Which of the following parameters would he not consider as an essential indicator?",
      "choices": [
        {
          "id": 1,
          "text": "Treatment Completion Rate (TCR)"
        },
        {
          "id": 2,
          "text": "Prevalence rate (PR)"
        },
        {
          "id": 3,
          "text": "Rate of new cases with Grade II disabilities per 10 lakh population per year"
        },
        {
          "id": 4,
          "text": "Proportion of new cases correctly diagnosed"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The proportion of new cases correctly diagnosed is not included under essential indicators. It is a part of the quality of service indicators as per NLEP 2020.&nbsp;</p>\n<p>The <strong>essential indicators</strong> include:</p>\n<ul>\n<li>Annual new case detection rate (<strong>ANCDR</strong>) per 1 lakh population.</li>\n<li>Rate of new cases with grade II disabilities (<strong>G2D</strong>) per 10 lakh population per year.</li>\n<li>Treatment completion rate (<strong>TCR</strong>) as a proxy to cure rate.</li>\n<li>Prevalence rate (<strong>PR</strong>).</li>\n</ul>\n<p><strong>Additional epidemiological indicators</strong> include:</p>\n<ul>\n<li>Proportion of Grade II disabilities among new cases.</li>\n<li>Proportion of females among new cases.&nbsp;</li>\n<li>Proportion of multibacillary (MB) among new cases.</li>\n<li>Proportion of child (0- 14 years) among new cases.&nbsp;</li>\n<li>Child rate per 100,000 population.&nbsp;</li>\n<li>Scheduled Caste New Case Detection Rate.</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD7238",
      "difficulty": "medium"
    },
    {
      "text": "According to the ICMR's nutritional requirement for Indians guidelines 2020, the estimated average requirement (EAR) of proteins for a sedentary female is:",
      "choices": [
        {
          "id": 1,
          "text": "44g/d"
        },
        {
          "id": 2,
          "text": "36g/d"
        },
        {
          "id": 3,
          "text": "30g/d"
        },
        {
          "id": 4,
          "text": "43g/d"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>According to the RDA guidelines 2020, the estimated average requirement (EAR) of proteins for a female is&nbsp;36g/d</p>\n<p>It is 43g/d for males. Protein requirement does not vary with activity levels.&nbsp;</p>\n<p>&nbsp;</p>\n<p>Note:&nbsp;<br />RDA and EAR are distinct parameters and values are different for both</p><hr><h3>Related Pearl: Recommended Dietary Allowances For Energy And Protein For Indians</h3><table>\n<tbody>\n<tr>\n<td> </td>\n<td><strong>Category</strong></td>\n<td><strong>EAR - Energy(Kcal/D) </strong></td>\n<td><strong> RDA - Protein (g/D) </strong></td>\n</tr>\n<tr>\n<td>Man</td>\n<td>\n<ul>\n<li data-leveltext=\"\" data-font=\"Symbol\" data-listid=\"3\" aria-setsize=\"-1\" data-aria-posinset=\"1\" data-aria-level=\"1\">Sedentary work </li>\n<li data-leveltext=\"\" data-font=\"Symbol\" data-listid=\"3\" aria-setsize=\"-1\" data-aria-posinset=\"2\" data-aria-level=\"1\">Moderate work </li>\n<li data-leveltext=\"\" data-font=\"Symbol\" data-listid=\"3\" aria-setsize=\"-1\" data-aria-posinset=\"3\" data-aria-level=\"1\">Heavy work  </li>\n</ul>\n</td>\n<td>\n<ul>\n<li data-leveltext=\"\" data-font=\"Symbol\" data-listid=\"3\" aria-setsize=\"-1\" data-aria-posinset=\"1\" data-aria-level=\"1\">2110 </li>\n<li data-leveltext=\"\" data-font=\"Symbol\" data-listid=\"3\" aria-setsize=\"-1\" data-aria-posinset=\"2\" data-aria-level=\"1\">2710 </li>\n<li data-leveltext=\"\" data-font=\"Symbol\" data-listid=\"3\" aria-setsize=\"-1\" data-aria-posinset=\"3\" data-aria-level=\"1\">3470 </li>\n</ul>\n</td>\n<td>\n<ul>\n<li data-leveltext=\"\" data-font=\"Symbol\" data-listid=\"3\" aria-setsize=\"-1\" data-aria-posinset=\"1\" data-aria-level=\"1\">54</li>\n<li data-leveltext=\"\" data-font=\"Symbol\" data-listid=\"3\" aria-setsize=\"-1\" data-aria-posinset=\"2\" data-aria-level=\"1\">54</li>\n<li data-leveltext=\"\" data-font=\"Symbol\" data-listid=\"3\" aria-setsize=\"-1\" data-aria-posinset=\"3\" data-aria-level=\"1\">54</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td>Woman </td>\n<td>\n<ul>\n<li>Sedentary work </li>\n<li data-leveltext=\"\" data-font=\"Symbol\" data-listid=\"3\" aria-setsize=\"-1\" data-aria-posinset=\"2\" data-aria-level=\"1\">Moderate work </li>\n<li data-leveltext=\"\" data-font=\"Symbol\" data-listid=\"3\" aria-setsize=\"-1\" data-aria-posinset=\"3\" data-aria-level=\"1\">Heavy work </li>\n<li data-leveltext=\"\" data-font=\"Symbol\" data-listid=\"3\" aria-setsize=\"-1\" data-aria-posinset=\"4\" data-aria-level=\"1\">Pregnancy <br /><br /><br /></li>\n<li data-leveltext=\"\" data-font=\"Symbol\" data-listid=\"3\" aria-setsize=\"-1\" data-aria-posinset=\"5\" data-aria-level=\"1\">Lactation (0-6m) </li>\n<li data-leveltext=\"\" data-font=\"Symbol\" data-listid=\"3\" aria-setsize=\"-1\" data-aria-posinset=\"6\" data-aria-level=\"1\">Lactation (6-12m) </li>\n</ul>\n</td>\n<td>\n<ul>\n<li>1660</li>\n<li>2130</li>\n<li>2720 </li>\n<li>+340 (2nd trimester)<br />+452 (3rd trimester)</li>\n<li data-leveltext=\"\" data-font=\"Symbol\" data-listid=\"3\" aria-setsize=\"-1\" data-aria-posinset=\"5\" data-aria-level=\"1\">+600 </li>\n<li data-leveltext=\"\" data-font=\"Symbol\" data-listid=\"3\" aria-setsize=\"-1\" data-aria-posinset=\"6\" data-aria-level=\"1\">+520 </li>\n</ul>\n</td>\n<td>\n<ul>\n<li>46</li>\n<li data-leveltext=\"\" data-font=\"Symbol\" data-listid=\"3\" aria-setsize=\"-1\" data-aria-posinset=\"2\" data-aria-level=\"1\">46</li>\n<li data-leveltext=\"\" data-font=\"Symbol\" data-listid=\"3\" aria-setsize=\"-1\" data-aria-posinset=\"3\" data-aria-level=\"1\">46</li>\n<li data-leveltext=\"\" data-font=\"Symbol\" data-listid=\"3\" aria-setsize=\"-1\" data-aria-posinset=\"3\" data-aria-level=\"1\">+9.5(2nd trimester)<br />+22 (3rd trimester)<br /><br /></li>\n<li data-leveltext=\"\" data-font=\"Symbol\" data-listid=\"3\" aria-setsize=\"-1\" data-aria-posinset=\"5\" data-aria-level=\"1\">+17  </li>\n<li data-leveltext=\"\" data-font=\"Symbol\" data-listid=\"3\" aria-setsize=\"-1\" data-aria-posinset=\"6\" data-aria-level=\"1\">+13 </li>\n</ul>\n</td>\n</tr>\n<tr>\n<td>Infant</td>\n<td>\n<ul>\n<li>0-6 months</li>\n<li>6-12 months</li>\n</ul>\n</td>\n<td>\n<ul>\n<li>530</li>\n<li>660</li>\n</ul>\n</td>\n<td>\n<ul>\n<li>8.0</li>\n<li>10.5</li>\n</ul>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p><strong>Dietary Reference Intakes</strong></p>\n<ul>\n<li>Recommended Dietary Allowance (RDA) - The average daily dietary intake that is sufficient to meet the requirements of almost all individuals in a group</li>\n<li>Estimated Average Requirement (EAR) - A nutrient intake value that is estimated to meet the requirements of half the individuals in a group</li>\n</ul>\n<p>The EAR for an <strong>elderly male </strong>(&gt;60 years) is <strong>1700 Kcal/D</strong> and for an <strong>elderly female </strong>(&gt;60 years) is <strong>1500 Kcal/D</strong>.</p>\n<p>Note: There is no RDA for energy. The EAR is equivalent to Estimated Energy Requirement (EER).</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD5733",
      "difficulty": "medium"
    },
    {
      "text": "The histological examination of the heart of a patient who died due to heart failure is given below.  What underlying condition did the patient most likely have?",
      "choices": [
        {
          "id": 1,
          "text": "Hypertrophic cardiomyopathy"
        },
        {
          "id": 2,
          "text": "Restrictive cardiomyopathy"
        },
        {
          "id": 3,
          "text": "Arrhythmogenic cardiomyopathy"
        },
        {
          "id": 4,
          "text": "Dilated cardiomyopathy"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>In the given scenario, the histology image shows&nbsp;<strong>ninja-star</strong>&nbsp;like nuclei in myocytes. This is suggestive of <strong>dilated cardiomyopathy&nbsp;</strong>(DCM).</p>\n<p>These are non-specific findings but the presence of&nbsp;<strong>&ge; 5% myocytes</strong> with <strong>ninja star</strong>-like nuclei are suggestive of <strong>DCM.</strong> Here, DCM is due to <strong>titin-truncating mutations</strong>. Truncating mutations are those which shorten the coding sequence of the genes.&nbsp;</p>\n<p>Histologically they appear as variable myocyte hypertrophy and interstitial fibrosis. The nuclei are enlarged, bizarre and hyperchromatic exhibiting a ninja-star like appearance.&nbsp;</p>\n<p>The image given below explains the ninja star-like nuclei in the myocytes.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/93325a80f6ee42009e9064b507199a84x600x636.JPEG\" alt=\"Explanation Image\">",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/b72ce2790c9a4d3fa57437cb1dcac5aa.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD5039",
      "difficulty": "medium"
    },
    {
      "text": "You are posted as a junior resident in the Emergency Medicine department, where you have to resuscitate an 11-month-old infant who is not breathing and you cannot get the pulse. According to the AHA 2020 guidelines for the pediatric basic and advanced life support, you would be correct to perform all of the following steps except:",
      "choices": [
        {
          "id": 1,
          "text": "Administer  at least 20-30 breaths/min"
        },
        {
          "id": 2,
          "text": "Use a cuffed endotracheal tube for intubating this child"
        },
        {
          "id": 3,
          "text": "Apply cricoid pressure  during endotracheal intubation"
        },
        {
          "id": 4,
          "text": "Administer the initial dose of epinephrine within 5 minutes from the start of chest compressions"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>According to the AHA 2020 guidelines, routine use of cricoid pressure is <strong>not</strong> recommended during the endotracheal intubation of pediatric patients.</p>\n<p>It is reasonable to choose <strong>cuffed ETT</strong>s over uncuffed ETTs for intubating infants and children. When a cuffed ETT is used, attention should be paid to tube size, position, and cuff inflation pressure (usually &lt;20-25 cm H2O).</p>\n<p>For infants and children with a pulse but an absent or inadequate respiratory effort, it is reasonable to give 1 breath every 2 to 3 seconds <strong>(20-30 breaths/min)</strong>. For pediatric patients in any setting, it is reasonable to administer the<strong> initial dose of epinephrine within 5 minutes</strong> from the start of chest compressions.</p><hr><h3>Related Pearl: Adult cardiac arrest algorithm (Updated as per 2020 guidelines)</h3><p>The adult cardiac arrest algorithm is based on the AHA guidelines as shown below.&nbsp;</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/2bdbdbe380bd43f59ef07a42a15ff9bax1280x3518.JPEG\" alt=\"Pearl Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD6477",
      "difficulty": "hard"
    },
    {
      "text": "Which of the following is not true about the Ervebo vaccine for the given viral disease?",
      "choices": [
        {
          "id": 1,
          "text": "It is a live attenuated vaccine"
        },
        {
          "id": 2,
          "text": "It contains the viral DNA as immunogen"
        },
        {
          "id": 3,
          "text": "It is effective against the Zaire subtype"
        },
        {
          "id": 4,
          "text": "It uses recombinant vesicular stomatitis virus"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The given structure is that of the <strong>Ebola virus</strong>. <strong>Ervebo vaccine</strong> does not contain viral DNA. Ebola virus is an RNA virus.</p>\n<p><strong>Ervebo</strong> is a <strong>live attenuated vaccine</strong> approved by FDA to prevent Ebola infection. It contains recombinant vesicular stomatitis virus in which the native glycoprotein gene is replaced with the glycoprotein gene of the Ebola virus. It is <strong>effective against the Zaire subtype</strong> of the virus only which was responsible for the recent outbreak in Africa.It is indicated in individuals 18 years of age and older.</p>\n<p>It should be administered as a single 1 mL dose, intramuscularly. Anaphylaxis has been observed following administration.</p>\n<p>Limitations:</p>\n<p>The duration of protection conferred by this vaccine is unknown.<br />It does <strong>not</strong> protect against other species of <strong>Ebolavirus or Marburgvirus</strong>.<br />Effectiveness of the vaccine when administered concurrently with antiviral medication, immune globulin (IG), and/or blood or plasma transfusions is unknown</p>\n<p>Vaccine virus RNA has been detected in blood, saliva, urine, and fluid from skin vesicles of vaccinated adults.</p>\n<p>The most common local adverse events were injection-site pain, swelling, and redness.<br />The most common systemic adverse events following vaccination were headache, feverishness, muscle pain, fatigue, joint pain, nausea, arthritis, rash and abnormal sweating.</p>\n<p>Ebola virus is an enveloped virus with helical symmetry. Its genetic content is single-stranded RNA bound in negative-sense. <span data-preserver-spaces=\"true\">Ebola virus shows a</span><strong><span data-preserver-spaces=\"true\"> bowl of spaghetti appearance. </span></strong><span data-preserver-spaces=\"true\">This virus has the <strong>highest mortality rate</strong> (25–90%) of all viral hemorrhagic fevers. </span>Patients are susceptible to reinfection even after a complete cure.</p>\n<p><span data-preserver-spaces=\"true\">The infection is common in Sudan and Zaire provinces in Africa. The incubation period of the disease is </span><strong><span data-preserver-spaces=\"true\">2 to 21</span></strong><span data-preserver-spaces=\"true\"> days. Symptoms include </span>fever, intense weakness, vomiting, diarrhea, rashes, and, in extreme cases, internal and external bleeding. The current treatment is mainly supportive.</p>\n<p> </p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/8024afd1771f4d538aad0a6b1824768c.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD5091",
      "difficulty": "medium"
    },
    {
      "text": "After having undergone training under the DAKSHATA program, you implement the usage of the safe childbirth checklists. Which of the following need to be recorded as part of the checklist on admission?<div class='question-desc-html'><ol>\n<li>Whether Partograph monitoring was done</li>\n<li>HIV status of the mother</li>\n<li>Availability of soap, water, and gloves</li>\n<li>Referral needs of the mother</li>\n<li>Whether a birth companion was encouraged to accompany the mother at labor, birth, and till discharge</li>\n</ol></div>",
      "choices": [
        {
          "id": 1,
          "text": "2, 4 and 5 only"
        },
        {
          "id": 2,
          "text": "1 and 2 only"
        },
        {
          "id": 3,
          "text": "1, 2, 3, 4, and 5"
        },
        {
          "id": 4,
          "text": "1, 2, 3, and 4 only"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>Under the DAKSHATA scheme, the Safe Childbirth Checklist used on admission requires all of the above parameters to be recorded</p>\n<p>The <strong>Ministry of Health and Family Welfare</strong> (MoHFW) has developed an initiative termed ‘Dakshata’ to improve the quality of care at the delivery points of the country through a focused program that includes</p>\n<ul>\n<li>a concise training package for <strong>competency enhancement </strong>for <strong>Medical Officers, Nurses, and ANMs</strong></li>\n<li>developing a system of<strong> post-training follow-up </strong>and<strong> mentoring</strong></li>\n<li>ensuring the <strong>availability </strong>of essential commodities,<strong> </strong>supplies, and equipment in the labor rooms</li>\n<li>strengthening the capacity of the facilities and the system to measure the quality of care regularly.</li>\n</ul>\n<p>The goal of the initiative:<br />To <strong>improve the quality of maternal and newborn care</strong> during the<strong> intra</strong>- and<strong> immediate postpartum period</strong>, through <strong>providers</strong> who are <strong>competent and confident (Dakshata).</strong></p>\n<p>The technical content of the training will be organized around four pause points:</p>\n<ul>\n<li>At the time of admission before birth</li>\n<li>Just before pushing or at cesarean section</li>\n<li>Soon after delivery (within 1 hour)</li>\n<li>At the time of discharge</li>\n</ul>\n<p>The checklists to be used are as below:</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/b8f50423e0304854b945cdb4bd20c2b3x571x712.PNG\" alt=\"Explanation Image\"><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/1ec2d7c512504de99bccf9f6a4834ff2x567x730.PNG\" alt=\"Explanation Image\"><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/d7dc891a55784e4f9b28fb7f96735409x559x733.PNG\" alt=\"Explanation Image\"><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/c7ff7b4314ae41d6a1a16886bc96e35dx545x727.PNG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD5729",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is a topical androgen receptor inhibitor that you can prescribe in a 16-year-old with the following condition?",
      "choices": [
        {
          "id": 1,
          "text": "Adapalene"
        },
        {
          "id": 2,
          "text": "Tazarotene"
        },
        {
          "id": 3,
          "text": "Tretinoin"
        },
        {
          "id": 4,
          "text": "Clascoterone"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The image shows the presence&nbsp;of&nbsp;<strong>papules&nbsp;</strong>and&nbsp;<strong>pustules</strong>&nbsp;with an&nbsp;<strong>erythematous base</strong>&nbsp;with few comedones, suggestive of moderate acne vulgaris.&nbsp; <strong>Clascoterone</strong>&nbsp;is the&nbsp;<strong>topical androgen receptor inhibitor</strong>&nbsp;that can be prescribed to this patient.</p>\n<p>Clascoterone is approved by the FDA in 2020 in the treatment of<strong> acne vulgaris </strong>in individuals<strong> aged&nbsp;&ge; 12 years</strong>. It is one of the alternative topical therapies.&nbsp;</p>\n<p>The mechanism of action of clascosterone is that it&nbsp;competes with the androgens, specifically <strong>dihydrotestosterone</strong>, for binding to the androgen receptor. This leads to <strong>inhibition</strong> of the<strong> sebum production</strong> and the <strong>inflammatory pathways</strong>.&nbsp;</p>\n<p>The <strong>adverse effects </strong>are <strong>skin irritation</strong> and in some cases hypothalamic-pituitary-adrenal axis suppression.&nbsp;</p>\n<p><strong>Acne</strong> is a&nbsp;<strong>polymorphic inflammatory</strong>&nbsp;disease of the&nbsp;<strong>pilosebaceous</strong>&nbsp;<strong>unit</strong>, frequently affecting the face, back and chest.&nbsp;<strong>Precipitating factors</strong> include:</p>\n<ul>\n<li>Lifestyle and environmental factors, diet, BMI, smoking and alcohol use, menstrual cycle, stress and sleep deprivation</li>\n<li><strong>Drugs</strong> like corticosteroids, anticonvulsants, etc</li>\n</ul>\n<p><strong>Severity</strong> of acne according to lesion type and extent:</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Type of acne</strong></td>\n<td><strong>Description</strong></td>\n</tr>\n<tr>\n<td>1. <strong>Comedonal</strong></td>\n<td>\n<div class=\"page\" title=\"Page 2376\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>- Non‐inflamed lesions<br />- Open comedones/blackheads<br />- Closed (whiteheads) comedones</p>\n</div>\n</div>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td>2. <strong>Mild</strong></td>\n<td>\n<div class=\"page\" title=\"Page 2376\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>- Non‐inflamed lesions<br />- Inflammatory lesions &lt;5 mm</p>\n</div>\n</div>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td>3. <strong>Moderate</strong></td>\n<td>\n<div class=\"page\" title=\"Page 2376\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>- Non‐inflamed lesions<br />- Papulopustular lesions</p>\n</div>\n</div>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td>4. <strong>Severe</strong></td>\n<td>\n<div class=\"page\" title=\"Page 2376\">\n<div class=\"page\" title=\"Page 2376\">\n<div class=\"page\" title=\"Page 2376\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>- Deep-seated inflammatory lesions<br />- Nodules and deep pustules<br />- Small nodules are &gt;5 mm; large nodules are &gt;1 cm<br />- Painful lesions with exudative sinus tracts, disfiguring tissue destruction and scarring<br /><br /><strong>Acne conglabata:</strong></p>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n<div class=\"page\" title=\"Page 2376\">\n<div class=\"page\" title=\"Page 2376\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>- Multiple grouped comedones<br />- Papules, tender inflammatory nodules of varying sizes, suppurative and coalesce to form sinus tract<br />- Extensive scarring</p>\n</div>\n</div>\n</div>\n</div>\n</div>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p><strong>Assessment</strong> of acne includes:</p>\n<ul>\n<li>Leed's photometric grading scale</li>\n<li>Comprehensive acne severity system (CASS)</li>\n</ul>\n<p>Management:&nbsp;</p>\n<ul>\n<li>Mild acne -&nbsp;\n<ul>\n<li>Comedonal acne&nbsp;-&nbsp;<strong>topical retinoid</strong></li>\n<li>Papular and pustular acne -&nbsp;<strong>topical retinoid </strong>and<strong> topical antibiotics</strong></li>\n</ul>\n</li>\n<li>Moderate papular or pustular acne&nbsp;and nodular acne -&nbsp;<strong>oral antibiotic + topical retinoid &plusmn;</strong><strong>&nbsp;benzoyl peroxide</strong></li>\n<li>Severe&nbsp;nodular and&nbsp;conglobate acne -&nbsp;<strong>oral isotretinoin</strong></li>\n<li>Other therapies -&nbsp; topical niacinamide, salicylic acid, chemical peels , lasers and photodynamic therapy</li>\n<li><strong>Novel drugs -&nbsp;</strong>\n<ul>\n<li>Drugs that target&nbsp;both <strong>retinoic acid receptors -beta</strong> and&nbsp;<strong>-gamma -&nbsp;</strong>\n<ul>\n<li>Adapalene</li>\n<li><strong>Tazarotene</strong>&nbsp;</li>\n<li>Tretinoin</li>\n</ul>\n</li>\n<li>Topical androgen receptor inhibitor - 1% <strong>clascoterone </strong>cream</li>\n</ul>\n</li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/58e50466bb94419194130673399b5f7ax1280x5399.JPEG\" alt=\"Explanation Image\"><hr><h3>Related Pearl: Key Chart to help differentiate lesions on face</h3><p><strong>Key Chart to help Differentiate Lesions on face</strong></p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/0a5140c64ee04126a3fec16990765703x1280x2116.JPEG\" alt=\"Pearl Image\"><p>&nbsp;</p>\n<p>The following images show the findings in -</p>\n<ul>\n<li><strong>Melasma</strong></li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/1b24d22d7e6a4de493c0d240ebd6ec77x512x379.PNG\" alt=\"Pearl Image\"><p>&nbsp;</p>\n<ul>\n<li><strong>Rosacea</strong></li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/0b3b7051b30c4603b4fc56b6170151f5x484x237.PNG\" alt=\"Pearl Image\"><p>&nbsp;</p>\n<ul>\n<li>Butterfly-shaped malar rash in<strong> SLE&nbsp;</strong></li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/96558496ccf84739a55a7acab31585ffx512x584.PNG\" alt=\"Pearl Image\"><p>&nbsp;</p>\n<ul>\n<li><strong>Acne</strong></li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/22d3e7b84f47471a8b58f938dc1a03f2x640x480.JPEG\" alt=\"Pearl Image\"><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/8897f6677285496484b6281ce6100c65x640x427.JPEG\" alt=\"Pearl Image\"><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/20f4612e49014dcbb32ac3481718547fx640x480.JPEG\" alt=\"Pearl Image\"><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/f248bc3b24f94e969561e2bf7be0b6b7x800x536.JPEG\" alt=\"Pearl Image\"><p>&nbsp;</p>\n<ul>\n<li><strong>Nevus of Ota</strong></li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/0f16c38775234b8789ab421ee8988755x512x494.PNG\" alt=\"Pearl Image\"><p>&nbsp;</p>\n<ul>\n<li><strong>Portwine stain</strong></li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/2ff136c533da46809a1e8615c5c9afa2x1280x959.5486600846262.JPEG\" alt=\"Pearl Image\"><p>&nbsp;</p>\n<ul>\n<li><strong>Infantile hemangioma</strong></li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/828bdd67837445a583f2c34441ecc984x450x600.JPEG\" alt=\"Pearl Image\"><hr><h3>Related Pearl: Global Alliance Algorithm for Acne Treatment</h3><p><strong>Global Alliance Algorithm for Acne Treatment</strong></p>\n<p><strong>Image: </strong>Global Alliance Algorithm for Improving Outcomes in acne</p><img src=\"https://cdn1.dailyrounds.org/uploads/d0c11e3325124df49bac9104eabccaebx686x530.JPEG\" alt=\"Pearl Image\"><p>BPO - Benzoyl peroxide</p><hr><h3>Related Pearl: Important Syndromes Related to Acne</h3><p><strong>Important Syndromes Related to Acne</strong></p>\n<p><strong>I. SAPHO syndrome</strong></p>\n<ol>\n<li>Synovitis</li>\n<li>Acne</li>\n<li>Pustulosis</li>\n<li>Hyperostosis</li>\n<li>Osteitis</li>\n</ol>\n<p><strong>II. HAIR-AN syndrome</strong></p>\n<ol>\n<li>Hyperandrogenism (HA)</li>\n<li>Insulin Resistance (IR)</li>\n<li>Acanthosis Nigricans(AN)</li>\n</ol>\n<p><strong>III. SAHA syndrome</strong></p>\n<ol>\n<li>Seborrhoea</li>\n<li>Acne</li>\n<li>Hirsutism</li>\n<li>Androgenetic alopecia</li>\n</ol>\n<p><strong>IV. PAPA syndrome</strong></p>\n<ol>\n<li>Pyogenic Arthritis (PA)</li>\n<li>Pyoderma gangrenosum (P)</li>\n<li>Acne(A)</li>\n</ol>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/22cd588c7dc84df6ba9340c77d8bb63b.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD4795",
      "difficulty": "hard"
    },
    {
      "text": "The given image shows newly discovered salivary gland tissues seen on PSMA (prostate-specific membrane antigen) PET/CT. These salivary gland tissues primarily overlie the _____",
      "choices": [
        {
          "id": 1,
          "text": "Torus tubarius"
        },
        {
          "id": 2,
          "text": "Rosenmüllers’ fossa"
        },
        {
          "id": 3,
          "text": "Eustachian tube"
        },
        {
          "id": 4,
          "text": "Maxillary sinus"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The given PSMA PET/CT shows the <strong>recently discovered</strong> pair of&nbsp;<strong>nasopharyngeal salivary glands</strong> which are present&nbsp;over the<strong> torus tubarius</strong>, the cartilaginous structure which supports the entrance of the eustachian tube. These newly&nbsp;identified glands have been named the &ldquo;<strong>tubarial salivary glands&rdquo;</strong>.</p>\n<p>The glands extend from the pharyngeal wall to the Rosenm&uuml;llers&rsquo; fossa. The gland cells showed almost 100% cytoplasmic expression of PSMA, similar to the PSMA-ligand uptake of minor salivary glands in the palate. Bilateral PSMA-positive areas were seen on PSMA PET/CT which extend from the skull base along the posterolateral pharyngeal wall, on the pharyngeal side of the superior pharyngeal constrictor muscle, with a PSMA-positive mass overlying the <strong>torus tubarius</strong>.</p>\n<p>PSMA PET/CT is positron emission tomography/computed tomography with prostate-specific membrane antigen ligands.</p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/db5fff3a2ca84b33b165c6abc3ea0db8.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD5956",
      "difficulty": "medium"
    },
    {
      "text": "A 7-day-old infant was brought with complaints of profuse watery diarrhea and severe dehydration. On detailed evaluation, labs showed metabolic acidosis and electron microscopy of small bowel biopsy showed characteristic intracellular microvillus inclusions. Mutations in which of the following genes is associated with this condition?",
      "choices": [
        {
          "id": 1,
          "text": "Microsomal triglyceride transfer protein"
        },
        {
          "id": 2,
          "text": "MYO5B"
        },
        {
          "id": 3,
          "text": "SMAD4"
        },
        {
          "id": 4,
          "text": "FOXP3"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The given scenario is suggestive of<strong>&nbsp;microvillus inclusion disease </strong>(MVID) which is associated with<strong> MYO5B gene </strong>mutations.&nbsp;</p>\n<p>Microvillus inclusion disease<strong>&nbsp;</strong>or Davidson disease&nbsp;is an <strong>autosomal recessive</strong> disorder due to mutations of MYO5B gene. This gene encodes a motor protein that is required for the transport of normal nutrients, ions, water, and plasma membrane components. Hence, it leads to <strong>defective</strong> <strong>vesicular</strong> <strong>transport</strong> that causes deficient brush-border assembly.</p>\n<p>Clinical features of MVID are:</p>\n<ul>\n<li>Profuse watery,<strong> secretory diarrhea -</strong> before 3 months of age (often in the <strong>first few days of life</strong>)</li>\n<li>Metabolic acidosis</li>\n<li>Hypotonic dehydration</li>\n</ul>\n<p>Diagnosis of MVID include:</p>\n<ul>\n<li>Electron microscopy -\n<ul>\n<li><strong>Inclusion containing microvilli</strong> in the apical cytoplasm of the intestinal cells.</li>\n<li>Brush border microvilli are poorly developed with only a few/blunted microvilli</li>\n</ul>\n</li>\n<li><strong>Immunostaining</strong> of<strong> villin</strong>&nbsp;(the brush border protein)</li>\n<li><strong>CD10 </strong>immunohistochemistry to detect microvillus inclusions</li>\n</ul>\n<p>Treatment is total parenteral nutrition and small bowel transplantation.</p>\n<p>The following electron microscopy image shows characteristic intracytoplasmic inclusions that are lined by intact microvilli along the absorptive surfaces of the intestinal cells.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/648fb7a031904bbda4684f848b63a921x1280x1179.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD7856",
      "difficulty": "medium"
    },
    {
      "text": "What was the 2020 Nobel Prize in Physiology or Medicine awarded for?",
      "choices": [
        {
          "id": 1,
          "text": "Discovery of how cells sense and adapt to oxygen availability"
        },
        {
          "id": 2,
          "text": "Discovery of hepatitis C virus"
        },
        {
          "id": 3,
          "text": "Discovery of cancer therapy by inhibition of negative immune regulation"
        },
        {
          "id": 4,
          "text": "Molecular mechanisms controlling the circadian rhythm"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><span data-preserver-spaces=\"true\">The Nobel Prize in Physiology or Medicine<strong> 2020</strong> was awarded jointly to&nbsp;</span>Harvey J. Alter, Michael Houghton, and Charles M. Rice<span data-preserver-spaces=\"true\">&nbsp;for <strong>the</strong></span><strong>&nbsp;discovery of hepatitis C</strong> virus.</p>\n<p>The given image shows Harvey J. Alter, Michael Houghton, and Charles M. Rice.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/b787ffa2af694174a80744081c23fa3dx800x450.JPEG\" alt=\"Explanation Image\"><p><span data-preserver-spaces=\"true\">The Nobel Prize in Physiology or Medicine<strong>&nbsp;2017</strong>&nbsp;was awarded jointly to Jeffrey C. Hall, Michael Rosbash, and Michael W. Young&nbsp;</span>for their discoveries of<strong><span data-preserver-spaces=\"true\"> molecular mechanisms </span></strong>controlling the<strong><span data-preserver-spaces=\"true\"> circadian rhythm.</span></strong></p>\n<p><span data-preserver-spaces=\"true\">The Nobel Prize in Physiology or Medicine&nbsp;<strong>2018</strong>&nbsp;was awarded jointly to</span><strong><span data-preserver-spaces=\"true\">&nbsp;</span></strong><span data-preserver-spaces=\"true\">James P. Allison and Tasuku Honjo for their discovery of</span><strong><span data-preserver-spaces=\"true\">&nbsp;cancer therapy </span></strong>by <strong><span data-preserver-spaces=\"true\">inhibition of negative immune regulation.</span></strong></p>\n<p><span data-preserver-spaces=\"true\">The Nobel Prize in Physiology or Medicine&nbsp;<strong>2019</strong>&nbsp;was awarded jointly to William G. Kaelin Jr., Sir Peter J. Ratcliffe, and Gregg L. Semenza for their discoveries of</span><strong><span data-preserver-spaces=\"true\">&nbsp;how cells sense and adapt to oxygen availability.</span></strong></p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD5117",
      "difficulty": "medium"
    },
    {
      "text": "Mr. Ramesh is a 55-year-old man who has pledged for cornea donation. History of which of the following diseases would render his cornea unfit for transplantation?<div class='question-desc-html'><ol>\n<li>Hypertension</li>\n<li>COVID-19 Infection</li>\n<li>Leprosy</li>\n<li>Diabetes mellitus</li>\n<li>Tetanus</li>\n</ol></div>",
      "choices": [
        {
          "id": 1,
          "text": "1, 2, 3, 4, 5"
        },
        {
          "id": 2,
          "text": "1, 3 and 5"
        },
        {
          "id": 3,
          "text": "2, 3, 4, 5"
        },
        {
          "id": 4,
          "text": "2, 3, 5"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>Diabetes and hypertension are not considered as a contraindication for carrying out cornea donation.</p>\n<p><strong>Contraindications</strong> for eye donation include <strong>Hepatitis B, Hepatitis C, HIV, syphilis, leprosy, tetanus, and COVID-19</strong>.</p>\n<p>In view of the recent pandemic, COVID -19 has also been included as a contraindication for eye donation as per the eye bank 2020 guidelines.</p>\n<p><strong>Contraindications for transplantation: </strong>These include conditions with a potential risk of transmission of local or systemic communicable disease from donor to recipient.</p>\n<ul>\n<li>Death of unknown cause.</li>\n<li>Death with progressive neurodegenerative diseases like\n<ul>\n<li>Chronic idiopathic demyelinating polyneuropathy</li>\n<li>Amyotrophic lateral sclerosis</li>\n<li>Multiple sclerosis</li>\n<li>Huntington’s chorea</li>\n<li>Alzheimer’s disease</li>\n<li>Myasthenia gravis</li>\n<li>Parkinson’s syndrome</li>\n<li>Creutzfeldt-Jakob disease</li>\n</ul>\n</li>\n<li>Active meningitis, viral encephalitis</li>\n<li>Active septicemia at the time of death</li>\n<li>Active viral hepatitis</li>\n<li>Congenital rubella</li>\n<li>Reye’s syndrome</li>\n<li>Suspected rabies and persons who, within the past six months, were bitten by an animal suspected to be infected with rabies</li>\n<li>Active miliary tuberculosis</li>\n<li>Hepatitis B surface antigen-positive donors, Hepatitis C seropositive donors</li>\n<li>HTLV-I or HTLV-II infection</li>\n<li>HIV seropositive donors</li>\n<li>Active syphilis or seropositive for syphilis.</li>\n<li><strong>Leprosy</strong></li>\n<li><strong>COVID-19 i</strong><strong>nfection</strong></li>\n<li><strong>Tetanus</strong></li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD5094",
      "difficulty": "medium"
    },
    {
      "text": "A 30-year-old male presented with an asymptomatic unilateral neck mass. Biopsy revealed a tumor arising from carotid body bifurcation which secreted norepinephrine. Various other laboratory and radiological investigations rule out pheochromocytoma in this patient. Which of the following syndrome would cause this tumor without pheochromocytoma?",
      "choices": [
        {
          "id": 1,
          "text": "Von Hippel Lindau syndrome"
        },
        {
          "id": 2,
          "text": "MEN 2A"
        },
        {
          "id": 3,
          "text": "Hereditary paraganglioma type 3"
        },
        {
          "id": 4,
          "text": "Polycythemia paraganglioma syndrome"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Hereditary paraganglioma type 3</strong>&nbsp; is associated with isolated <strong>paraganglioma without pheochromocytoma</strong>. Type 1 and 4 are associated with both pheochromocytoma and paragangliomas</p>\n<p>Paragangliomas are neuroendocrine cell tumors arising from sympathetic or parasympathetic ganglia. Sympathetic paraganglioma secretes catecholamines whilst parasympathetic are silent. They may be incidentally detected.&nbsp;Around 70% of extra-adrenal paragangliomas occur in the head and neck.</p>\n<p>Adrenal medullary pheochromocytomas are the most common paraganglioma.</p>\n<p>Paragangliomas typically develop in two locations:</p>\n<ul>\n<li>Paravertebral paraganglia (organ of Zuckerkandl). These tumors have <strong>sympathetic</strong> connections and stain positively for<strong> chromaffin</strong>, as they <strong>produce catecholamines.</strong></li>\n<li>Paraganglia related to the great vessels of the head and neck, especially the aorticopulmonary chain, including the carotid bodies (carotid body tumor), aortic bodies, jugulotympanic ganglia ( glomus tympanicum or jugulare), the vagus nerve, and clusters located around the oral cavity, nose, nasopharynx, larynx, and orbit. These have&nbsp;<strong>parasympathetic</strong> innervation and do <strong>not</strong> usually produce catecholamines.</li>\n</ul>\n<p>The <strong>carotid body tumor</strong> is a <strong>parasympathetic paraganglioma</strong>. It is usually less than 6 cm in diameter and arises around the <strong>bifurcation of the common carotid artery</strong>. The tumor&nbsp;is red-pink to brown colored, and the microscopic features show&nbsp;nests (zellballen) of round to oval chief cells with abundant, clear or granular, eosinophilic cytoplasm and uniform, round to ovoid&nbsp;nuclei, surrounded by delicate vascular septae. There is scanty cellular pleomorphism and mitoses.&nbsp;The <strong>chief cells</strong> stain positive for&nbsp;<strong>chromogranin, synaptophysin, neuron-specific enolase, CD56, and CD57. </strong></p>\n<p>The supporting spindle-shaped stromal cells called <strong>sustentacular cells</strong>&nbsp;are positive for <strong>S-100 protein</strong>.</p>\n<p>Electron microscopy shows well-demarcated <strong>neuroendocrine granules</strong> in<strong> paravertebral, functioning</strong> tumors.</p>\n<p>&nbsp;</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Syndrome</strong></td>\n<td><strong>Gene</strong></td>\n<td><strong>Associated lesions</strong></td>\n<td><strong>Other features</strong></td>\n</tr>\n<tr>\n<td>Hereditary paraganglioma 1</td>\n<td>SDHD</td>\n<td>Pheochromocytoma, paraganglioma</td>\n<td>&nbsp;GIST</td>\n</tr>\n<tr>\n<td>Hereditary paraganglioma 3</td>\n<td>SDHC</td>\n<td>Paraganglioma</td>\n<td>&nbsp;GIST</td>\n</tr>\n<tr>\n<td>Hereditary paraganglioma&nbsp;4&nbsp;</td>\n<td>SDHB</td>\n<td>Pheochromocytoma, paraganglioma</td>\n<td>&nbsp;GIST</td>\n</tr>\n<tr>\n<td>Polycythemia paraganglioma syndrome</td>\n<td>EPAS1</td>\n<td>Pheochromocytoma, paraganglioma</td>\n<td>Polycythemia</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;<br /><br /><br />&nbsp;&nbsp;</p>\n<p><strong>Other options:</strong></p>\n<p>VHL Syndrome is associated with both phaeochromocytoma and paraganglioma.</p>\n<p>MEN 2A presents with phaeochromocytoma, paraganglioma, medullary thyroid carcinoma, and parathyroid hyperplasia.</p>\n<p>Polycythemia paraganglioma syndrome has paraganglioma, pheochromocytoma, and polycythemia.</p>\n<p>&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD5112",
      "difficulty": "medium"
    },
    {
      "text": "Which drug has been approved by the FDA to treat Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping?",
      "choices": [
        {
          "id": 1,
          "text": "Eteplirsen"
        },
        {
          "id": 2,
          "text": "Viltolarsen"
        },
        {
          "id": 3,
          "text": "Deflazocort"
        },
        {
          "id": 4,
          "text": "Risdiplam"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Viltolarsen</strong> is an antisense oligonucleotide indicated for the treatment of Duchenne muscular dystrophy, which has been approved by the FDA in patients who have a <strong>confirmed mutation </strong>of the <strong>DMD gene that is</strong> <strong>amenable to exon 53 skipping.</strong></p>\n<p>Viltolarsen injection is administered as an<strong> intravenous infusion </strong>over<strong> 60 minutes.</strong></p>\n<p>Serum cystatin C, urine dipstick, and urine protein-to-creatinine ratio should be measured before starting Viltolarsen. Kidney function should be monitored in patients on this drug. The most common adverse reactions with this drug were upper respiratory tract infection, injection site reaction, cough and fever.</p>\n<p><strong>Muscle Dystrophy:</strong></p>\n<p>Duchenne and Becker muscular dystrophy are caused by loss-of-function mutations in the<strong> dystrophin gene on the X chromosome</strong>. Dystrophin is one of the <strong>largest human genes</strong>. Dystrophin provides mechanical stability to the myofiber and its cell membrane during muscle contraction. Defects in the complex can lead to small membrane tears that pemits calcium influx, resulting in myofiber degeneration.</p>\n<p>Duchenne muscular dystrophy is associated with <strong>deletions or frame-shift mutations</strong> that result in the <strong>total absence of dystrophin. </strong></p>\n<p>In Becker muscular dystrophy, the mutations lead to the synthesis of a <strong>truncated version of dystrophin, </strong>which <strong>retains some</strong> of the <strong>function</strong>.<strong> </strong>Immunohistochemical studies for dystrophin show the absence of the normal sarcolemmal staining pattern in Duchenne muscular dystrophy and reduced staining in Becker muscular dystrophy.</p>\n<p><strong>Definitive therapy</strong> aims at restorating the dystrophin levels in skeletal and cardiac muscle fibers.</p>\n<p>One approach involves the expression of antisense RNAs which alter RNA splicing which allow <strong>“skipping” of exons</strong> containing deleterious mutations, and permitting the expression of a truncated and partially functional, dystrophin protein.</p>\n<p>Using drugs that <strong>promote ribosomal “read-through” of stop codons</strong>, which may enable the expression of some dystrophin protein.</p>\n<p>Both of these approaches are mutation-specific and thus need to be tailored to individual patients.</p>\n<p><strong>Gene therapy</strong> (introduction of a normal dystrophin gene) is under investigation.</p><p><strong>ETEPLIRSEN</strong> is the first drug approved by the FDA to treat patients with Duchenne muscular dystrophy (DMD). It is specifically indicated for patients who have a <strong>confirmed mutation of the dystrophin gene amenable to exon 51 skipping</strong>, which affects approximately 13-14%of the patients with DMD.</p>\n<p><strong>Deflazacort</strong> is a <strong>corticosteroid</strong> indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older. Its efficacy is equivalent to prednisolone with the advantage of a lesser incidence of weight gain and other adverse effects.</p>\n<p><strong>Risdiplam</strong> is an <strong>orally bioavailable mRNA splicing modifier</strong> for the treatment of <strong>spinal muscular atrophy</strong> (SMA).</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD4796",
      "difficulty": "hard"
    },
    {
      "text": "Which of the following is not involved in efferocytosis?",
      "choices": [
        {
          "id": 1,
          "text": "Epithelial cell"
        },
        {
          "id": 2,
          "text": "Macrophage"
        },
        {
          "id": 3,
          "text": "Fibroblast"
        },
        {
          "id": 4,
          "text": "Free radicals"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Efferocytosis</strong> is a specialized type of phagocytosis, where <strong>apoptotic bodies</strong> are phagocytosed with the help of&nbsp;<strong>macrophages, epithelial cells</strong>, and <strong>fibroblast cells.</strong></p>\n<p>During this process, ligands bind to the apoptotic bodies and send &lsquo;<strong>eat me</strong>&rsquo; <strong>signals</strong>. These signals are recognized by receptors present on phagocytes that bind and engulf these cells.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD5037",
      "difficulty": "medium"
    },
    {
      "text": "The U.S. Food and Drug Administration has recently approved a drug called lumasiran as the first treatment for __________________",
      "choices": [
        {
          "id": 1,
          "text": "Homocystinuria type I"
        },
        {
          "id": 2,
          "text": "Hyperprolinemia type I"
        },
        {
          "id": 3,
          "text": "Primary hyperoxaluria type 1"
        },
        {
          "id": 4,
          "text": "Homocystinuria type II"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The U.S. Food and Drug Administration has approved <strong>lumasiran</strong> (Oxlumo) which&nbsp;is an <strong>HAO1-directed small interfering ribonucleic acid</strong> (siRNA) indicated for the <strong>treatment of primary hyperoxaluria type 1 (PH1).&nbsp;</strong>It is used to lower urinary oxalate levels in pediatric and adult patients.</p>\n<p>It&nbsp;<strong>decreases oxalate production&nbsp;</strong>and is designated as an<strong> orphan drug.&nbsp;</strong>Lumasiran (Oxlumo)&nbsp;injection is for <strong>subcutaneous use</strong>. Primary hyperoxaluria type I occurs due to the deficiency of the <strong>alanine</strong> <strong>glyoxalate aminotransferase</strong> in liver peroxisomes.&nbsp;There is a failure to catabolize glyoxylate formed by the deamination of glycine.&nbsp;This causes oxalate overproduction, leading to the formation of oxalate stones and subsequent kidney damage.</p>\n<p>Patients with PH1 produce excess oxalate, which can combine with calcium to cause kidney stones and deposits in the kidneys. This can lead to progressive kidney damage, resulting in kidney failure and the need for dialysis. As kidney function worsens, oxalate can build up and damage other organs, including the heart, bones and eyes.</p>\n<p>&nbsp;</p><hr><h3>Related Pearl: Amino acid Enzymatic Disorders and the Associated Enzymes</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Disorder</strong></p>\n</td>\n<td>\n<p><strong>Enzyme defect</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Phenylketonuria</p>\n</td>\n<td>\n<p>Phenylalanine hydroxylase</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Tyrosinosis (Tyrosinemia type I)</p>\n</td>\n<td>\n<p>Maleyl Acetate isomerase or Fumarylacetoacetate hydrolase</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Maple syrup urine disease&nbsp;</p>\n</td>\n<td>\n<p>Branched-chain alpha-keto acid dehydrogenase(BCKAD)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Alkaptonuria</p>\n</td>\n<td>\n<p>Homogentisate oxidase</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Albinism</p>\n</td>\n<td>\n<p>Tyrosinase</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Homocystinuria type I</p>\n</td>\n<td>\n<p>Cystathionine synthase</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Homocystinuria type II</p>\n</td>\n<td>\n<p>Defect in methylcobalamin formation</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Cystathioninuria</p>\n</td>\n<td>\n<p>Cystathionase</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Tyrosinemia type II or Richner-Hanhart syndrome</p>\n</td>\n<td>\n<p>Tyrosine transaminase or Tyrosine aminotransferase</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Primary hyperoxaluria</p>\n</td>\n<td>\n<p>Alanine glyoxalate aminotransferase</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Hypervalinemia</p>\n</td>\n<td>\n<p>Valine transaminase</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Isovaleric acidemia</p>\n</td>\n<td>\n<p>Isovaleryl CoA dehydrogenase</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Histidinemia</p>\n</td>\n<td>\n<p>Histidase</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Hyperprolinemia type I</p>\n</td>\n<td>\n<p>Proline oxidase</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD6535",
      "difficulty": "medium"
    }
  ]
}